List of Figures
Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2015–2022 20
Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2015–2022 21
Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2015–2022 22
Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2015–2022 23
Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2015–2022 25
Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006–2022 30
Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2006–2022 31
Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006–2022 32
Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006–2022 34
Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($bn), 2006–2022 35
Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006–2022 36
Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006–2022 37
Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 38
Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2016 39
Figure 15: Breakdown of Biologics in Ophthalmology Pipeline, 2016 40
Figure 16: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2016 41
Figure 17: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2016 42
Figure 18: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2016 43
Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 44
Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 45
Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 46
Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 47
Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 48
Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 49
Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 50
Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 51
Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2016 52
Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2015 53
Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 54
Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 55
Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016 56
Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 57
Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2015 58
Figure 34: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 59
Figure 35: Ophthalmology, Global, Market Size ($bn), 2015–2022 60
Figure 36: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2015–2022 62
Figure 37: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2015–2022 63
Figure 38: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2015–2022 64
Figure 39: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2015–2022 64
Figure 40: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2015–2022 65
Figure 41: Ophthalmology, Global, Revenue Forecast for Fovista($m), 2017–2022 66
Figure 42: Ophthalmology, Global, Revenue Forecast for SPK-RPE65 ($m), 2017–2022 67
Figure 43: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2017–2022 68
Figure 44: Ophthalmology, Global, Revenue Forecast for Rhopressa ($m), 2017–2022 69
Figure 45: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018–2022 70
Figure 46: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 71
Figure 47: Ophthalmology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 74
Figure 48: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2014–2022 75
Figure 49: Ophthalmology, Global, Revenues by Product Type, 2014–2022 76
Figure 50: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2015–2022 77
Figure 51: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2015–2022 78
Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2015–2022 79
Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2015–2022 80
Figure 54: Ophthalmology, Global, Ophthotech Annual Revenue Forecast ($m), 2015–2022 81
Figure 55: Ophthalmology, Global, Spark Therapeutics Annual Revenue Forecast ($m), 2015–2022 82
Figure 56: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2015–2022 83
Figure 57: Ophthalmology, Global, Companies by Type, 2016 84
Figure 58: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2016 85
Figure 59: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2015–2022 86
Figure 60: Ophthalmology Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, Top Four Companies ($bn), 2015–2022 87
Figure 61: Ophthalmology, Global, Licensing Deals, 2006–2016 89
Figure 62: Ophthalmology Global, Licensing Deals by Indication and Value, 2006–2016 90
Figure 63: Ophthalmology, Global, Licensing Deals, 2006–2016 91
Figure 64: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2016 92
Figure 65: Ophthalmology, Global, Co-development Deals, 2006–2016 95
Figure 66: Ophthalmology, Global, Co-development Deals, 2006–2016 96
Figure 67: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 97